Skip to main content
Premium Trial:

Request an Annual Quote

Predicine Receives CE-IVD Mark for Blood and Urine Liquid Biopsy Assay

NEW YORK – Molecular testing company Predicine said on Tuesday that its blood and urine cell-free DNA (cfDNA) assay, PredicineCare, has secured a CE-IVD mark.

The targeted next-generation sequencing (NGS) assay is developed to detect single nucleotide variants (SNVs), insertions and deletions (indels), DNA rearrangements (fusions), and copy number variations (CNVs) in patients diagnosed with cancer, according to the Hayward, California-based company.

Predicine said that the liquid biopsy-based PredicineCare can target 152 genes, including guideline-recommended gene targets that are known to be actionable and linked to available therapies or clinical trials.

With this CE-IVD mark, Predicine said it plans to commercialize PredicineCare in Europe as an in vitro diagnostic (IVD) test.

"Launching PredicineCare as the first CE-IVD marked product is a significant milestone and aligns with the organization's strategy to provide affordable and accessible molecular testing solution in the European market," said Shidong Jia, Predicine's founder and CEO, in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.